4/1
10:59 am
pmn
ProMIS Neurosciences, Inc. (NASDAQ: PMN) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $6.00 price target on the stock.
Medium
Report
ProMIS Neurosciences, Inc. (NASDAQ: PMN) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $6.00 price target on the stock.
3/31
07:11 am
pmn
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights [Yahoo! Finance]
Low
Report
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights [Yahoo! Finance]
3/31
07:00 am
pmn
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
Medium
Report
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
3/24
07:00 am
pmn
ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference
Medium
Report
ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer’s Disease/Parkinson’s Disease 2025 International Conference
3/13
07:07 am
pmn
ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting [Yahoo! Finance]
Medium
Report
ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting [Yahoo! Finance]
3/13
07:00 am
pmn
ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting
Medium
Report
ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting
3/11
07:30 am
pmn
ProMIS Neurosciences to Participate in the 37th Annual Roth Conference
High
Report
ProMIS Neurosciences to Participate in the 37th Annual Roth Conference
2/26
11:36 am
pmn
ProMIS Neurosciences, Inc. (NASDAQ: PMN) had its "buy" rating re-affirmed by analysts at Guggenheim.
Medium
Report
ProMIS Neurosciences, Inc. (NASDAQ: PMN) had its "buy" rating re-affirmed by analysts at Guggenheim.
2/25
08:04 am
pmn
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease [Yahoo! Finance]
High
Report
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease [Yahoo! Finance]
2/25
07:28 am
pmn
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease [Canadian Business Journal (Canada)]
High
Report
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease [Canadian Business Journal (Canada)]
2/25
07:00 am
pmn
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease
Medium
Report
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease
2/19
06:00 pm
pmn
ProMIS Neurosciences dismisses COO position [Seeking Alpha]
Medium
Report
ProMIS Neurosciences dismisses COO position [Seeking Alpha]
1/29
07:30 am
pmn
ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference
Low
Report
ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference
1/13
11:28 am
pmn
ProMIS Neurosciences Issues Letter to Shareholders [Canadian Business Journal (Canada)]
Low
Report
ProMIS Neurosciences Issues Letter to Shareholders [Canadian Business Journal (Canada)]
1/13
10:30 am
pmn
ProMIS Neurosciences Issues Letter to Shareholders
Low
Report
ProMIS Neurosciences Issues Letter to Shareholders
1/10
07:00 am
pmn
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease
Medium
Report
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease